Immix Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-15.43	-8.23	-24.38	-1.15	-0.97
Depreciation & Amortization	0.01	0	0	0	0
Share-Based Compensation	2.57	0.62	0.22	0	0
Other Operating Activities	1.48	0.2	22.57	0.74	0.18
Operating Cash Flow	-11.37	-7.41	-1.59	-0.4	-0.79
Capital Expenditures	-0.05	0	-0	0	-0.01
Investing Cash Flow	-0.05	0	-0	0	-0.01
Share Issuance / Repurchase	15.52	2.81	18.65	0	0
Debt Issued / Paid	0	-0.05	0.2	0	1.05
Other Financing Activities	-0.06	0.47	-	-	-
Financing Cash Flow	15.46	3.23	18.85	0	1.05
Exchange Rate Effect	0.03	-0.03	-0.01	0.06	0.02
Net Cash Flow	4.07	-4.21	17.25	-0.34	0.27
Free Cash Flow	-11.42	-7.41	-1.59	-0.4	-0.8
Free Cash Flow Per Share	-0.66	-0.53	-0.43	-0.12	-0.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).